sGC Pharma Overview

  • Founded
  • 2007
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

sGC Pharma General Information


Developer of therapeutic drugs designed for the treatment of Alzheimer's disease. The company's therapeutic drugs contain one protein or one gene that can be specifically targeted to reverse the disease, enabling patients to improve their cognition and memory.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • 101 Main Street
  • Suite 1750
  • Cambridge, MA 02142
  • United States
+1 (613) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

sGC Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business 30-Jun-2017 00000 Completed Out of Business
3. Grant 01-Sep-2013 00000 00000 Completed Generating Revenue
2. Grant 05-Dec-2008 $295K $600K Completed Startup
1. Early Stage VC (Series A) 19-Jun-2007 $600K $600K 00.00 Completed Startup
To view sGC Pharma’s complete valuation and funding history, request access »

sGC Pharma Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 0,000,000 00.000000 00.00 00 00 00 00 0.000
To view sGC Pharma’s complete cap table history, request access »

sGC Pharma Executive Team (4)

Name Title Board Seat Contact Info
Robert Bender Chief Executive Officer & Chairman
Greg Thatcher Chief Scientific Officer
Anthony Cieri Secretary
Doug Cowart Senior Vice President of Regulatory Affairs and Clinical Development
To view sGC Pharma’s complete executive team members history, request access »

sGC Pharma Board Members (1)

Name Representing Role Since
Robert Bender sGC Pharma Chief Executive Officer & Chairman 000 0000
To view sGC Pharma’s complete board members history, request access »